期刊文献+

血浆脑钠肽在心房纤颤患者中应用的临床意义分析 被引量:4

Clinical Significance of Plasama Brain Natriuretie Peptide in Patients with Atrial Fibrillation
下载PDF
导出
摘要 目的观察心房纤颤(房颤)对血浆脑钠肽(BNP)水平的影响并探讨其临床意义。方法采用美国博适-Triag干式快速定量(心力衰竭/心肌梗死)诊断仪床旁测定86例心功能正常房颤患者及30例无器质性心脏病窦性心律患者BNP水平。对房颤患者进行药物复律,测定复律前后血浆BNP水平。结果房颤患者BNP水平显著高于无器质性心脏病窦性心律患者(P<0.01)。房颤组中,复律成功组复律后的BNP水平显著下降(P<0.01);复律成功组复律前BNP水平明显低于未复律成功组(P<0.01)。结论房颤是影响BNP分泌的重要因素,BNP水平是预测房颤复律效果的重要指标,复律后BNP水平显著下降。 Objective To observe the plasma brain natriuretie peptide levels in patients with atrial fibrillation(AF)and its clinical significance.Methods The plasma BNP levels were measured at bedside in 86 cases of atrial fibrillation with normal heart function and 30 cases of normal sinus rhythm without structural heart diseases,using Biosite trige dry quantitative determination.Drugs on patients with atrial fibrillation to sinus rhythm,determination of plasma BNP levels before and after cardioversion.Results BNP levels were significantly higher than that of atrial fibrillation without structural heart diseases in sinus rhythm group(P<0.01).Of AF group,the sinus rhythm after successful cardioversion group of BNP level was significantly decreased(P<0.01);successful cardioversion to sinus rhythm group,BNP levels were significantly lower than before cardioversion success group(P<0.01).Conclusion Atrial fibrillation is an important factor affecting the secretion of BNP,BNP level is an important indicator to predict the effect of cardioversion in AF,after cardioversion BNP levels significantly decreased.
出处 《实用心脑肺血管病杂志》 2012年第1期20-21,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词 心房纤颤 脑纳肽 心脏病 Atrial fibrillation Brain natriuretie peptide Heart diseases
  • 相关文献

参考文献11

  • 1Mwangi W, Brown WC, Lewin HA, et al. DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induc
  • 2陈协兴,洪华山,王一波,江琼,陈良龙.脑钠素在慢性心力衰竭诊断、预后评估中的价值[J].中国循环杂志,2003,18(6):434-436. 被引量:17
  • 3McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells[J]. Blood, 2000,95( 11 ):3489-3497.
  • 4Brasel K, De Smedt T, Smith JL, et al. Generation of murine dendritic cells from flt3-1igand-supplemented bone marrow cultures[J]. Blood, 2000, 96(9):3029-3039.
  • 5Shurin GV, Chatta GS, Tourkova IL, et al. Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand[J]. Exp Gerontol, 2004, 39(2): 339-348.
  • 6Kataoka K, McGhee JR, Kobayashi R, et al. Nasal Flt3 Ligand cDNA Elicits CD11c (+)CD8 (+) Dendritic Cells for Enhanced Mucosal Immunity[J]. J Immunol,2004,172(6):3612-3169.
  • 7Peretz Y, Zhou ZF, Halwani F. In vivo generation of dendritic cells by intramuscular codelivery of FLT3 ligand and GM-CSF plasmids [J]. Mol Ther, 2002, 6(3):407-414.
  • 8Vasu C, Dogan RN, Holterman MJ, et al. Selective Induction of Dendritic Cells Using Granulocyte Macrophage-Colony Stimulating Factor, But Not fms-Like Tyrosine Kinase Receptor 3-Ligand,Activates Thyroglobulin-Specific CD4 (+)/CD25 (+) T Cells and Suppress
  • 9Sang H, Pisarev VM, Munger C, et al. Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity [ J ]. Vaccine, 2003, 21 (21-22) :3019-3029.
  • 10Pisarev VM, Parajuli P, Mosley RL, et al. Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine [J ]. Int J Immunopharmacol, 2000, 22 ( 11 ):865-876.

二级参考文献8

  • 1[1]Maeda K,Tsutamota T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J,1998,135 : 825-832.
  • 2[2]Maisel AS,Krishnaswamy P, Richards M, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med, 2002,347:161-167.
  • 3[3]Mcdonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet, 1998,351:9-13.
  • 4[5]Suzuki T, Yamaoki K, Nakajima O, et al. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels . Jpn Heart J, 2000,41: 205-214.
  • 5[6]Cowie MW.BNP: soon to become a routine measure in the care of patients with heart failure? Heart,2000,83:617-618.
  • 6[7]Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med, 2002, 39: 131-138.
  • 7[8]Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriureric peptide in cardiology.J Lab Clin Med, 1999, 134:437-444.
  • 8慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量:2414

共引文献17

同被引文献50

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部